Colorectal Cancer (CRC) Recruiting Phase 2 Trials for Leucovorin (DB00650)

Back to Colorectal Cancer (CRC)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

Indication	Status	Phase
DBCOND0031867 (Colorectal Cancer (CRC))	Recruiting	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT07809893	Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients	Treatment	Celecoxib (DB00482) Fluorouracil (DB00544) Irinotecan (DB00762) Ivonescimab (DB18931) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT07659795	A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer	Treatment	Cetuximab (DB00002) Fluorouracil (DB00544) Leucovorin (DB00650) Oxaliplatin (DB00526) Panitumumab (DB01269) VS-7375 (DB22888)
NCT06590259	A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM	Treatment	Bevacizumab (DB00112) Cetuximab (DB00002) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526) Sintilimab (DB15765)
NCT07604909	A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy	Treatment	Bevacizumab (DB00112) Cetuximab (DB00002) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650) Serplulimab (DB17451)
NCT07391618	Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU	Treatment	Bevacizumab (DB00112) Cetuximab (DB00002) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT06279351	Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer	Treatment	Cetuximab (DB00002) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526) Thalidomide (DB01041)
NCT07562490	A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer	Treatment	Bevacizumab (DB00112) Capecitabine (DB01101) Fluorouracil (DB00544) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT07562503	Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer	Treatment	Capecitabine (DB01101) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT07562711	Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer	Treatment	Capecitabine (DB01101) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT07474727	A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer	Treatment	AMT-676 (DB25063) Bevacizumab (DB00112) Cetuximab (DB00002) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT07011576	A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)	Treatment	Fluorouracil (DB00544) Fruquintinib (DB11679) Irinotecan (DB00762) Leucovorin (DB00650)
NCT06948448	A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer	Treatment	Bevacizumab (DB00112) Fluorouracil (DB00544) Leucovorin (DB00650) Nivolumab (DB09035) ONO-4578 (DB22389) Oxaliplatin (DB00526)
NCT06722183	Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities	Treatment	Fluorouracil (DB00544) Futibatinib (DB15149) Leucovorin (DB00650) Oxaliplatin (DB00526) Tislelizumab (DB14922)
NCT06640166	Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.	Treatment	Cetuximab (DB00002) Encorafenib (DB11718) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650)
NCT06475352	Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme	Treatment	Capecitabine (DB01101) Fluorouracil (DB00544) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT06293014	TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer	Treatment	Bevacizumab (DB00112) Capecitabine (DB01101) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526) Tipiracil (DB09343) Trifluridine (DB00432)
NCT06280495	Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients	Treatment	Bevacizumab (DB00112) Fluorouracil (DB00544) Leucovorin (DB00650) Oxaliplatin (DB00526) Serplulimab (DB17451)
NCT06184698	Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer	Treatment	Bevacizumab (DB00112) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650)
NCT06002789	Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC	Treatment	Fluorouracil (DB00544) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT05571644	Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer	Treatment	Cadonilimab (DB16680) Fluorouracil (DB00544) Fruquintinib (DB11679) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT05286814	PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma	Treatment	Dexamethasone (DB01234) Floxuridine (DB00322) Fluorouracil (DB00544) Gemcitabine (DB00441) Immunocytokine NHS-IL12 (DB17585) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT03874026	Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients	Treatment	Cetuximab (DB00002) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650)
NCT07047560	Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study	Treatment	Bevacizumab (DB00112) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650)
NCT05022030	First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes	Treatment	Capecitabine (DB01101) Cetuximab (DB00002) Fluorouracil (DB00544) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT07562659	Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer	Treatment	Capecitabine (DB01101) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526)